麻豆传媒

No efficacy difference between the two drugs in two phase III trials

Processing speed scores lower 4 years later for people with one or more baseline lesions

Clinical, radiologic measures remained stable or improved in both younger and older patients

Tough to pinpoint what is a long-term MS symptom and what is a long COVID symptom

Increased risk of physical, psychological, cognitive decline

Real-world data analysis compares oral disease-modifying therapies

No new relapses recorded after autologous transplant

Predictive enrichment could increase the power of future trials

Sensitivity, accuracy also high in prospective study

Ventricular enlargement was second strongest indicator

Subset of multiple sclerosis patients seroconverted after third dose, however

Urinary, kidney infections especially are more common for people with MS than others

The issue: some multiple sclerosis drugs may attenuate antibody responses to vaccination

North American data echoes findings from around the world